Table 1 population characteristics
From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
Characteristics | Number of patients | Percentage & range | P (Cox analysis for PFS) |
|---|---|---|---|
Gender | 56 | 100% | 0.050 |
Male | 33 | 58.9% | |
Female | 23 | 41.1% | |
Age at diagnosis | 0.982 | ||
Median (min–max) (year) | 24.5 | 9–63 | |
Pathological diagnosis | 56 | 100% | 0.087 |
Osteosarcoma | 22 | 39.3% | |
Ewing sarcoma | 10 | 17.9% | |
Synovial sarcoma | 6 | 10.7% | |
MPNSTa | 3 | 5.4% | |
Epithelioid sarcoma | 2 | 3.6% | |
UPSb | 4 | 7.1% | |
Fibrosarcoma | 1 | 1.8% | |
Chondrosarcoma | 3 | 5.4% | |
ASPSc | 3 | 5.4% | |
Othersd | 2 | 3.6% | |
Tumor grade | |||
Grade III | 56 | 100% | |
Location of primary disease | 56 | 100% | 0.374 |
Axial skeleton | 17 | 30.3% | |
Extremities | 37 | 66.1% | |
Otherse | 2 | 3.6% | |
Localization of relapse | 56 | 100% | 0.541 |
Localized | 3 | 5.6% | |
Metastatic | 41 | 73.2% | |
Both | 12 | 21.4% | |
Type of metastasis | 53 | 94.6% | 0.197 |
Lung only | 40 | 71.4% | |
Bone only | 3 | 5.4% | |
Both | 5 | 8.9% | |
Othere | 5 | 8.9% | |
Time interval from initial chemotherapy to using apatinib | 0.584 | ||
Median (min–max) (month) | 15.6 | 0.9–373.9 | |
Number of previous treatment lines | 56 | 100% | 0.231 |
0 | 5 | 8.9% | |
1 | 37 | 66.1% | |
2 | 12 | 21.4% | |
> 2 | 2 | 3.6% | |
Follow-up time | |||
Median (min–max) (month) | 6.0 | 0.7–18.0 | |